ANTLER Phase 1 trial of CB-010 at dose level 1

Caribou Biosciences Corporate Presentation December 12 2022

12-month clinical data from cohort 1 in the ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x10^6 CAR-T cells)

Format

JPEG

Source

Caribou Biosciences, Inc.

Downloads